While attention has focused on the brutal sell-off tearing through the technology sector and the AI trade, something notable has been happening in another corner of the market. The biotech and pharmaceutical sector has held its ground and, relatively speaking, done so impressively.
As the Nasdaq-100 and the high-flying AI names have been clobbered in recent sessions, healthcare names, especially biotech and pharma, have refused to break down. That kind of relative strength amid a broad risk-off move is exactly what's worth paying attention to.
